GSK recalls three lots of children’s cough medicine in US
GlaxoSmithKline has voluntarily recalled two lots of Children's Robitussin® Honey Cough and Chest Congestion DM and one lot of Children's Dimetapp® Cold and Cough in the US.
List view / Grid view
GlaxoSmithKline has voluntarily recalled two lots of Children's Robitussin® Honey Cough and Chest Congestion DM and one lot of Children's Dimetapp® Cold and Cough in the US.
Indian authorities have given their first approval for the oral antiviral favipiravir for treatment of COVID-19 to Glenmark Pharmaceuticals.
A new oil-based oral formulation of prostate cancer drug abiraterone acetate could enable a smaller dose of the drug to be effective and reduce possible side effects, a study has shown.
The UK government has approved dexamethasone to be available on the NHS, following clinical trials proving its efficacy at reducing the risk of death for COVID-19 patients.
The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
New findings reveal that the 200 clinical trials impacted and delayed by COVID-19 are now continuing or have completed their course.
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
A survey of US adults has revealed that the majority are very or somewhat worried that big pharma will take advantage of the COVID-19 pandemic to increase the price of drugs.
Due to a potentially faulty and incorrectly engaged child-resistant container closure, Torbay Pharmaceuticals has announced a recall of certain Epistatus (midazolam) batches.
The drug candidate SFX-01 is set to be studied in Phase II/III trials to test its efficacy at treating acute respiratory distress syndrome (ARDS), a complication of COVID‐19.
According to an expert, Indian pharmaceutical companies will have to price remdesivir cautiously to ward off generic competition in the near future.
After evidence suggesting hydroxychloroquine has no benefit against COVID-19, the MHRA has suspended further recruitment to clinical trials investigating the drug in the UK.
A Phase III trial has been launched to study whether baricitinib, an oral JAK1/JAK2 inhibitor, is effective at combatting COVID-19 in hospitalised patients.
The EDQM and European Pharmacopoeia have decided to share Ph. Eur. quality standards for COVID-19 vaccine developers to support their research.
A clinical trial has shown that an inexpensive steroid called dexamethasone could prevent death in one out of eight ventilated COVID-19 patients and one out of 25 patients receiving oxygen only.